NEPHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
NEPHROS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$3.68+0.03 (+0.82%)
Close on Oct 19, 2026
- Market cap
- $40.89M
- P/E (TTM)
- 23.0
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
48.9%
5M of 11M shares
Institutional holders
33
7 new, 1 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Charles E. Davidson | 616,945 | 5.68% | 13G (passive) | Sep 14, 2026 |
| Topline Capital Management, LLC | 595,334 | 5.60% | 13G (passive) | Aug 4, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NEPH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Wexford Capital LP | 3,600,552 | 33.15% | $12.85M | – | 1.64% |
| Topline Capital Management, LLC | 535,698 | 4.93% | $1.91M | −46,269 | 0.50% |
| Vanguard Capital Management LLC | 198,643 | 1.83% | $709.16K | – | 0.00% |
| Morgan Stanley | 128,915 | 1.19% | $460.23K | +18,000 | 0.00% |
| Cornerstone Capital, Inc. | 128,700 | 1.19% | $459.46K | – | 0.04% |
| Bard Associates Inc | 118,003 | 1.09% | $421.27K | −3,199 | 0.09% |
| Renaissance Technologies LLC | 77,504 | 0.71% | $276.69K | −21,896 | 0.00% |
| Geode Capital Management, LLC | 70,263 | 0.65% | $250.92K | −2,662 | 0.00% |
| Mesirow Financial Investment Management, Inc. | 60,000 | 0.55% | $214.20K | −60,000 | 0.00% |
| HighTower Advisors, LLC | 59,710 | 0.55% | $213.17K | – | 0.00% |
| Navellier & Associates Inc | 53,479 | 0.49% | $190.92K | +34,353 | 0.02% |
| Essex Investment Management Co LLC | 38,927 | 0.36% | $138.97K | −57 | 0.02% |
| Vanguard Fiduciary Trust Co | 36,901 | 0.34% | $131.74K | – | 0.00% |
| Blair William & Co/Il | 36,249 | 0.33% | $129.41K | – | 0.00% |
| Citadel Advisors LLC | 29,044 | 0.27% | $103.69K | +8,156 | 0.00% |
| Dimensional Fund Advisors LP | 22,164 | 0.20% | $79.13K | +1,419 | 0.00% |
| BlackRock, Inc. | 18,822 | 0.17% | $67.20K | New | 0.00% |
| De Lisle Partners LLP | 17,400 | 0.16% | $62.12K | −7,600 | 0.01% |
| Northern Trust Corp | 16,706 | 0.15% | $59.64K | +5,878 | 0.00% |
| State Street Corp | 15,698 | 0.14% | $56.04K | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 33 | 5M | 48.9% | 7 / 7 | 9 / 1 | 0M | 0M |
| Q1 2026 | 27 | 5M | 49.4% | 3 / 6 | 9 / 10 | 1M | 0M |
| Q4 2025 | 35 | 5M | 48.8% | 14 / 11 | 5 / 3 | 0M | 0M |
| Q3 2025 | 24 | 5M | 46.2% | 4 / 4 | 9 / 1 | 0M | 0M |
| Q2 2025 | 21 | 5M | 44.7% | 4 / 8 | 5 / 1 | 0M | 0M |
| Q1 2025 | 18 | 5M | 43.0% | 1 / 5 | 5 / 1 | 0M | 0M |
| Q4 2024 | 18 | 5M | 43.4% | 3 / 2 | 7 / 2 | 0M | 0M |
| Q3 2024 | 17 | 4M | 39.5% | 0 / 5 | 6 / 2 | 0M | 0M |
| Q2 2024 | 19 | 4M | 39.9% | 4 / 5 | 6 / 3 | 0M | 0M |
| Q1 2024 | 18 | 4M | 39.4% | 3 / 8 | 3 / 3 | 0M | 0M |
| Q4 2023 | 18 | 4M | 40.2% | 4 / 6 | 2 / 0 | 0M | 0M |
| Q3 2023 | 14 | 4M | 39.5% | 1 / 3 | 3 / 3 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of NEPH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 130,901 | 1.21% | $467.32K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 67,742 | 0.62% | $241.84K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 33,707 | 0.31% | $123.37K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 17,742 | 0.16% | $63.34K | 0.00% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 11,571 | 0.11% | $42.35K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 9,528 | 0.09% | $34.87K | 0.00% | May 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 4,811 | 0.04% | $16.31K | 0.00% | Jul 31, 2026 |
| U.S. Sustainability Core 1 Portfolio | 3,337 | 0.03% | $11.31K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 3,085 | 0.03% | $11.29K | 0.00% | May 31, 2026 |
| U.S. Core Equity 2 Portfolio | 2,725 | 0.03% | $9.24K | 0.00% | Jul 31, 2026 |
| Dimensional US Core Equity 1 ETF | 2,462 | 0.02% | $8.35K | 0.00% | Jul 31, 2026 |
| U.S. Core Equity 1 Portfolio | 2,333 | 0.02% | $7.91K | 0.00% | Jul 31, 2026 |
| U.S. Social Core Equity 2 Portfolio | 2,332 | 0.02% | $7.91K | 0.00% | Jul 31, 2026 |
| U.S. Vector Equity Portfolio | 1,419 | 0.01% | $4.81K | 0.00% | Jul 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,080 | 0.01% | $3.86K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert R. Banks Jr. | President and CEO | 190,000 | 1.75% | Mar 25, 2026 |
| Judy Krandel | Chief Financial Officer | 68,861 | 0.63% | Mar 25, 2026 |
| Holdings LLC Amron | Director | 187,005 | 1.72% | Sep 16, 2026 |
| Arthur H. Amron | Director | 140,874 | 1.30% | Sep 16, 2026 |
| Lisa Marie Nettis | Director | 1,622 | 0.01% | Nov 13, 2025 |
| Oliver J. Spandow | Director | 122,881 | 1.13% | Nov 13, 2025 |
| Alisa Lask | Director | 48,629 | 0.45% | Jan 3, 2025 |
| Joseph Michael Harris | Director | 17,693 | 0.16% | Jan 3, 2025 |
| GP LLC Wexford | 10% owner | 245,437 | 2.26% | Sep 16, 2026 |
| Joseph Jacobs | 10% owner | 30,047,742 | 276.68% | Sep 16, 2026 |
| Capital Lp Wexford | 10% owner | 3,650,529 | 33.61% | Sep 16, 2026 |
| Charles E. Davidson | 10% owner | 3,608,667 | 33.23% | Sep 16, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Holdings LLC Amron Director | Sep 14, 2026 | Other | +22,710 | $3.95 | $89.70K | 25,546 |
| Holdings LLC Amron Director | Sep 14, 2026 | Other | +17,749 | – | – | 158,623 |
| Holdings LLC Amron Director | Sep 14, 2026 | Other | +2,836 | – | – | 2,836 |
| GP LLC Wexford 10% owner | Sep 14, 2026 | Other | −3,355,111 | – | – | 189,377 |
| GP LLC Wexford 10% owner | Sep 14, 2026 | Other | −22,710 | $3.95 | $89.70K | 166,667 |
| Joseph Jacobs 10% owner | Aug 18, 2026 | Option exercise | +812 | $3.60 | $2.92K | 56,872 |
| Arthur H. Amron Director | Aug 12, 2026 | Award | +2,418 | – | – | 140,874 |
| Arthur H. Amron Director | May 11, 2026 | Award | +3,574 | – | – | 138,456 |
| Judy Krandel Chief Financial Officer | Mar 23, 2026 | Option exercise | +68,861 | $1.71 | $117.75K | 68,861 |
| Robert R. Banks Jr. President and CEO | Mar 23, 2026 | Option exercise | +120,000 | $1.44 | $172.80K | 190,000 |
| Arthur H. Amron Director | Mar 16, 2026 | Award | +3,610 | – | – | 134,882 |
| Lisa Marie Nettis Director | Nov 10, 2025 | Award | +1,622 | – | – | 1,622 |
| Arthur H. Amron Director | Nov 10, 2025 | Award | +5,391 | – | – | 131,272 |
| Oliver J. Spandow Director | Nov 10, 2025 | Award | +8,036 | – | – | 122,881 |
| Arthur H. Amron Director | Jan 1, 2025 | Award | +22,418 | – | – | 125,881 |
| Oliver J. Spandow Director | Jan 1, 2025 | Award | +33,241 | – | – | 114,845 |
| Arthur H. Amron Director | May 30, 2024 | Buy | +3,000 | $2.24 | $6.72K | 103,463 |
| Arthur H. Amron Director | May 28, 2024 | Buy | +2,000 | $2.22 | $4.44K | 100,463 |
| Robert R. Banks Jr. President and CEO, Director | May 16, 2024 | Buy | +50,000 | $2.24 | $112.00K | 70,000 |
| Arthur H. Amron Director | Mar 13, 2024 | Other | +91,463 | – | – | 98,463 |
| GP LLC Wexford 10% owner | Mar 13, 2024 | Other | −91,463 | – | – | 56,060 |
| Arthur H. Amron Director | Mar 12, 2024 | Buy | +7,000 | $2.45 | $17.15K | 7,000 |
| Oliver J. Spandow Director | Dec 13, 2023 | Award | +14,294 | – | – | 81,604 |
| Arthur H. Amron Director | Dec 13, 2023 | Award | +9,291 | – | – | 9,291 |
| Joseph Michael Harris Director | Dec 13, 2023 | Award | +9,291 | – | – | 17,693 |
| Alisa Lask Director | Dec 13, 2023 | Award | +9,291 | – | – | 48,629 |
| Robert R. Banks Jr. President and CEO, Director | Dec 7, 2023 | Buy | +18,000 | $2.20 | $39.60K | 20,000 |
| Robert R. Banks Jr. President and CEO, Director | Aug 15, 2023 | Buy | +1,901 | $1.69 | $3.21K | 2,000 |
| Robert R. Banks Jr. President and CEO, Director | Aug 14, 2023 | Buy | +99 | $1.50 | $149 | 99 |
| Oliver J. Spandow Director | Jan 5, 2023 | Award | +42,481 | – | – | 67,310 |
| Tom Gwydir Director | Jan 5, 2023 | Award | +27,613 | – | – | 43,226 |
| Alisa Lask Director | Jan 5, 2023 | Award | +27,613 | – | – | 39,338 |
| Joseph Michael Harris Director | Jan 5, 2023 | Award | +8,402 | – | – | 8,402 |
| Arthur H. Amron Director | Jan 5, 2023 | Award | +27,613 | – | – | 27,613 |
| Andrew Astor President, CEO & CFO, Director | Mar 5, 2022 | Option exercise | +14,815 | $2.70 | $40.00K | 92,773 |
| Wesley S. Lobo Chief Marketing Officer | Feb 16, 2022 | Tax withholding | −6,389 | $4.80 | $30.67K | 35,168 |
| Tom Gwydir Director | Dec 14, 2021 | Award | +4,582 | – | – | 15,613 |
| Arthur H. Amron Director | Dec 14, 2021 | Award | +4,582 | – | – | 4,582 |
| Alisa Lask Director | Dec 14, 2021 | Award | +4,582 | – | – | 11,725 |
| Oliver J. Spandow Director | Dec 14, 2021 | Award | +5,429 | – | – | 24,829 |
| Wesley S. Lobo Chief Marketing Officer | Aug 20, 2021 | Buy | +1,000 | $7.92 | $7.92K | 41,557 |
| Tom Gwydir Director | Aug 18, 2021 | Buy | +5,000 | $7.64 | $38.20K | 11,031 |
| Andrew Astor President & CEO, Director | Aug 18, 2021 | Buy | +2,500 | $7.77 | $19.43K | 77,958 |
| Andrew Astor President & CEO, Director | Aug 17, 2021 | Buy | +2,500 | $7.67 | $19.18K | 75,458 |
| Capital Lp Wexford Director, 10% owner | Jun 1, 2021 | Option exercise | +66,667 | $2.70 | $180.00K | 3,544,492 |
| Daron Evans CEO Specialty Renal Products | May 27, 2021 | Tax withholding | −349 | $2.70 | $942 | 8,669 |
| Daron Evans CEO Specialty Renal Products | May 27, 2021 | Tax withholding | −349 | $2.70 | $942 | 8,947 |
| Daron Evans CEO of Specialty Renal Product | May 24, 2021 | Option exercise | +1,111 | $2.70 | $3.00K | 9,018 |
| Daron Evans CEO of Specialty Renal Product | May 24, 2021 | Option exercise | +1,111 | $2.70 | $3.00K | 9,296 |
| Wesley S. Lobo Chief Marketing Officer | Feb 16, 2021 | Award | +40,557 | – | – | 40,557 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +2,956 | $4.14 | $12.24K | 97,795 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +3,765 | $3.60 | $13.55K | 101,560 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +4,477 | $4.50 | $20.15K | 106,037 |
| GP LLC Wexford Director, 10% owner | Jan 27, 2021 | Option exercise | +3,556 | $4.59 | $16.32K | 94,839 |
| Arthur H. Amron Director | Jan 6, 2021 | Award | +3,666 | – | – | 3,666 |
| Alisa Lask Director | Jan 6, 2021 | Award | +3,666 | – | – | 7,143 |
| Malcolm C. Persen Director | Jan 6, 2021 | Award | +5,921 | – | – | 48,774 |
| Tom Gwydir Director | Jan 6, 2021 | Award | +3,666 | – | – | 6,031 |
| Oliver J. Spandow Director | Jan 6, 2021 | Award | +3,666 | – | – | 19,400 |
| Charles E. Davidson Director, 10% owner | Jan 6, 2021 | Award | +3,196 | – | – | 3,196 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.